{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:28:12Z","timestamp":1792409292855,"version":"4.4.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["453,989,101"],"award-info":[{"award-number":["453,989,101"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["507803309"],"award-info":[{"award-number":["507803309"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic and Interventional Imaging"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.diii.2024.04.004","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T01:42:46Z","timestamp":1715650966000},"page":"400-406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["The cutting edge: Promising oncology radiotracers in clinical development"],"prefix":"10.1016","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8979-2010","authenticated-orcid":false,"given":"Jorge D.","family":"Oldan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2897-4694","authenticated-orcid":false,"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diii.2024.04.004_bib0001","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2967\/jnumed.117.197988","article-title":"Appropriate use criteria for (18)F-FDG PET\/CT in restaging and treatment response assessment of malignant disease","volume":"58","author":"Jadvar","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0002","series-title":"Nuclear medicine and molecular imaging: the requisites","author":"Janis","year":"2020"},{"key":"10.1016\/j.diii.2024.04.004_bib0003","series-title":"Essentials of nuclear medicine and molecular imaging","author":"Mettler","year":"2019"},{"key":"10.1016\/j.diii.2024.04.004_bib0004","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.diii.2023.06.001","article-title":"Nodular fasciitis: PET\/CT and MR imaging features","volume":"104","author":"Barat","year":"2023","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.diii.2024.04.004_bib0005","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2967\/jnumed.117.202275","article-title":"Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors","volume":"59","author":"Hope","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0006","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2967\/jnumed.121.263262","article-title":"Appropriate use criteria for prostate-specific membrane antigen PET imaging","volume":"63","author":"Jadvar","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0007","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.diii.2022.02.005","article-title":"Diagnosis of early biochemical recurrence after radical prostatectomy or radiation therapy in patients with prostate cancer: state of the art","volume":"103","author":"Zhang-Yin","year":"2022","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.diii.2024.04.004_bib0008","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2967\/jnumed.123.265420","article-title":"Summary: appropriate use criteria for estrogen receptor-targeted PET imaging with 16alpha-(18)F-fluoro-17beta-fluoroestradiol","volume":"64","author":"Ulaner","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0009","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.3390\/diagnostics13122018","article-title":"FAPI PET\/CT imaging-an updated review","volume":"13","author":"Chandekar","year":"2023","journal-title":"Diagnostics"},{"key":"10.1016\/j.diii.2024.04.004_bib0010","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2967\/jnumed.123.265594","article-title":"Fibroblast activation protein inhibitor-based radionuclide therapies: current status and future directions","volume":"64","author":"Ora","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0011","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/RLU.0000000000004438","article-title":"Comparison of the detection performance between FAP and FDG PET\/CT in various cancers: a systemic review and meta-analysis","volume":"48","author":"Chang","year":"2023","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0012","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3948873","article-title":"Could fibroblast activation protein (FAP)-specific radioligands be considered as pan-tumor agents?","volume":"2022","author":"Roustaei","year":"2022","journal-title":"Contrast Media Mol Imaging"},{"key":"10.1016\/j.diii.2024.04.004_bib0013","doi-asserted-by":"crossref","first-page":"10136","DOI":"10.3390\/ijms241210136","article-title":"Diagnostic performance of positron emission tomography with fibroblast-activating protein inhibitors in gastric cancer: a systematic review and meta-analysis","volume":"24","author":"Rizzo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diii.2024.04.004_bib0014","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3390\/ph16121664","article-title":"Diagnostic accuracy of [(68)Ga]Ga labeled fibroblast-activation protein inhibitors in detecting head and neck cancer lesions using positron emission tomography: a systematic review and a meta-analysis","volume":"16","author":"Rizzo","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.diii.2024.04.004_bib0015","doi-asserted-by":"crossref","first-page":"51251","DOI":"10.1097\/RLU.0000000000004189","article-title":"Interobserver agreement rates on fibroblast activation protein inhibitor-directed molecular imaging and therapy","volume":"47","author":"Serfling","year":"2022","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0016","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2967\/jnumed.123.266390","article-title":"Initial experience with (68)Ga-FAP-2286 PET imaging in patients with urothelial cancer","volume":"65","author":"Koshkin","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0017","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cpet.2023.12.006","article-title":"PET\/computed tomography transformation of oncology: kidney and urinary tract cancers","volume":"19","author":"Oldan","year":"2024","journal-title":"PET Clin"},{"key":"10.1016\/j.diii.2024.04.004_bib0018","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.3390\/ijms23116125","article-title":"New developments in carbonic anhydrase IX-targeted fluorescence and nuclear imaging agents","volume":"23","author":"Chen","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diii.2024.04.004_bib0019","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.2011.41.2445","article-title":"Positron emission tomography\/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial","volume":"31","author":"Divgi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.diii.2024.04.004_bib0020","doi-asserted-by":"crossref","first-page":"BA602","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA602","article-title":"Results from phase 3 study of 89Zr-DFO-girentuximab for PET\/CT imaging of clear cell renal cell carcinoma (ZIRCON)","volume":"41","author":"Shuch","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.diii.2024.04.004_bib0021","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s00259-019-04358-9","article-title":"Lesion detection by [(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG-PET\/CT in patients with newly diagnosed metastatic renal cell carcinoma","volume":"46","author":"Verhoeff","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2024.04.004_bib0022","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1158\/1078-0432.CCR-22-0921","article-title":"[89Zr]Zr-DFO-girentuximab and [18F]FDG PET\/CT to predict watchful waiting duration in patients with metastatic clear-cell renal cell carcinoma","volume":"29","author":"Verhoeff","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.diii.2024.04.004_bib0023","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/RLU.0000000000000670","article-title":"Initial experience using 99mTc-MIBI SPECT\/CT for the differentiation of oncocytoma from renal cell carcinoma","volume":"40","author":"Rowe","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0024","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3390\/diagnostics13040593","article-title":"Molecular imaging diagnosis of renal cancer using (99m)Tc-sestamibi SPECT\/CT and girentuximab PET-CT-current evidence and future development of novel techniques","volume":"13","author":"Tataru","year":"2023","journal-title":"Diagnostics"},{"key":"10.1016\/j.diii.2024.04.004_bib0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1053\/j.semnuclmed.2023.09.002","article-title":"Advances in PET imaging of the CXCR4 receptor: [(68)Ga]Ga-Pentixafor","volume":"54","author":"Lindenberg","year":"2024","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0026","first-page":"1687","article-title":"Imaging of C-X-C motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using (68)Ga-pentixafor PET","volume":"63","author":"Buck","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0027","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20211272","article-title":"Imaging CXCR4 receptors expression for staging multiple myeloma by using (68)Ga-pentixafor PET\/CT: comparison with (18)F-FDG PET\/CT","volume":"95","author":"Shekhawat","year":"2022","journal-title":"Br J Radiol"},{"key":"10.1016\/j.diii.2024.04.004_bib0028","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00259-019-04605-z","article-title":"Chemokine receptor-4 targeted PET\/CT with (68)Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to (18)F-FDG PET\/CT","volume":"47","author":"Pan","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2024.04.004_bib0029","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7150\/thno.16576","article-title":"[(68)Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma: comparison to [(18)F]FDG and laboratory values","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.diii.2024.04.004_bib0030","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.3390\/cancers12082333","article-title":"18F-FDG, 11C-methionine, and 68Ga-pentixafor PET\/CT in patients with smoldering multiple myeloma: imaging pattern and clinical features","volume":"12","author":"Zhou","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.diii.2024.04.004_bib0031","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s12149-021-01652-1","article-title":"Prognostic significance of (68)Ga-pentixafor PET\/CT in multiple myeloma recurrence: a comparison to (18)F-FDG PET\/CT and laboratory results","volume":"35","author":"Kuyumcu","year":"2021","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0032","doi-asserted-by":"crossref","first-page":"567","DOI":"10.7150\/thno.48620","article-title":"CXCR4 PET imaging of mantle cell lymphoma using [(68)Ga]pentixafor: comparison with [(18)F]FDG-PET","volume":"11","author":"Mayerhoefer","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.diii.2024.04.004_bib0033","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.120.257279","article-title":"Improved primary staging of marginal-zone lymphoma by addition of CXCR4-directed PET\/CT","volume":"62","author":"Duell","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0034","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2967\/jnumed.119.226134","article-title":"(68)Ga-pentixafor PET\/CT for imaging of chemokine receptor 4 expression in Waldenstrom macroglobulinemia\/lymphoplasmacytic lymphoma: comparison to (18)F-FDG PET\/CT","volume":"60","author":"Luo","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0035","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13550-021-00852-0","article-title":"Semi-quantitative measurements of chemokine receptor 4-targeted (68)Ga-pentixafor PET\/CT in response assessment of Waldenstrom macroglobulinemia\/lymphoplasmacytic lymphoma","volume":"11","author":"Pan","year":"2021","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.diii.2024.04.004_bib0036","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.7150\/thno.31032","article-title":"Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [(68)Ga]Ga-pentixafor-PET\/MRI","volume":"9","author":"Haug","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.diii.2024.04.004_bib0037","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/blood.2021013239","article-title":"CXCR4 PET\/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line h. pylori eradication","volume":"139","author":"Mayerhoefer","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.diii.2024.04.004_bib0038","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2967\/jnumed.120.241703","article-title":"CXCR4-targeted PET imaging of central nervous system B-cell lymphoma","volume":"61","author":"Herhaus","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0039","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/RLU.0000000000003404","article-title":"Assessment of central nervous system lymphoma based on CXCR4 expression in vivo using 68Ga-pentixafor PET\/MRI","volume":"46","author":"Starzer","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0040","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11307-021-01664-3","article-title":"CXCR4-directed PET\/CT with [(68)Ga]pentixafor in central nervous system lymphoma: a comparison with [(18)F]FDG PET\/CT","volume":"24","author":"Chen","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.diii.2024.04.004_bib0041","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2967\/jnumed.115.161034","article-title":"First experience with chemokine receptor CXCR4-targeted PET imaging of patients with solid cancers","volume":"57","author":"Vag","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0042","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3389\/fonc.2019.00770","article-title":"CXCR4-directed imaging in solid tumors","volume":"9","author":"Werner","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.diii.2024.04.004_bib0043","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13550-018-0442-0","article-title":"PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma","volume":"8","author":"Vag","year":"2018","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.diii.2024.04.004_bib0044","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/RLU.0000000000004674","article-title":"Impact of CXCR4-directed PET\/CT on staging and proposed oncologic management in patients with digestive system tumors","volume":"48","author":"Weich","year":"2023","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0045","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1007\/s00259-023-06486-9","article-title":"The evidence-based role of catecholaminergic PET tracers in neuroblastoma: a systematic review and a head-to-head comparison with mIBG scintigraphy","volume":"51","author":"Piccardo","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2024.04.004_bib0046","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/RLU.0000000000004447","article-title":"18 F-MFBG PET\/CT Is an effective alternative of 68 Ga-DOTATATE PET\/CT in the evaluation of metastatic pheochromocytoma and paraganglioma","volume":"48","author":"Wang","year":"2023","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0047","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1007\/s00259-022-06063-6","article-title":"[(18)F]mFBG PET-CT for detection and localization of neuroblastoma: a prospective pilot study","volume":"50","author":"Samim","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2024.04.004_bib0048","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1007\/s00259-023-06221-4","article-title":"[(18)F]MFBG PET\/CT outperforming [(123)I]MIBG SPECT\/CT in the evaluation of neuroblastoma","volume":"50","author":"Wang","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2024.04.004_bib0049","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2967\/jnumed.119.232553","article-title":"Diagnosis, treatment response, and prognosis: the role of (18)F-DOPA PET\/CT in children affected by neuroblastoma in comparison with (123)I-mIBG scan: the first prospective study","volume":"61","author":"Piccardo","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0050","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00259-011-1938-2","article-title":"Comparison of 18F-DOPA PET\/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study","volume":"39","author":"Piccardo","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2024.04.004_bib0051","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2967\/jnumed.112.102772","article-title":"Characterization of neuroblastic tumors using 18F-FDOPA PET","volume":"54","author":"Lu","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0052","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s13139-022-00762-6","article-title":"Comparative role of (18)F-DOPA PET\/CT and (131)I-MIBG scintigraphy in neuroblastoma and application of Curie and SIOPEN scoring systems in (18)F-DOPA PET\/CT","volume":"56","author":"Hemrom","year":"2022","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2024.04.004_bib0053","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","article-title":"European Association of Nuclear Medicine practice guideline\/Society of Nuclear Medicine and Molecular Imaging procedure standard 2019 for radionuclide imaging of pheochromocytoma and paraganglioma","volume":"46","author":"Taieb","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2024.04.004_bib0054","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cpet.2023.12.012","article-title":"PET\/Computed tomography transformation of oncology: immunotherapy assessment","volume":"19","author":"Ghodsi","year":"2024","journal-title":"PET Clin"},{"key":"10.1016\/j.diii.2024.04.004_bib0055","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.3390\/cancers15235675","article-title":"Clinical application of immunoPET targeting checkpoint inhibitors","volume":"15","author":"Abenavoli","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.diii.2024.04.004_bib0056","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.3390\/cancers15245886","article-title":"ImmunoPET targeting receptor tyrosine kinase: clinical applications","volume":"15","author":"Linguanti","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.diii.2024.04.004_bib0057","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2967\/jnumed.122.264470","article-title":"Noninvasive assessment of human epidermal growth factor receptor 2 in esophagogastric cancer using (89)Zr-trastuzumab PET: a pilot study","volume":"64","author":"Lumish","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0058","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1158\/1078-0432.CCR-22-3769","article-title":"Determinants of survival with combined HER2 and PD-1 blockade in metastatic esophagogastric cancer","volume":"29","author":"Maron","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.diii.2024.04.004_bib0059","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1007\/s00259-018-4099-8","article-title":"(89)Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up","volume":"45","author":"Bensch","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2024.04.004_bib0060","doi-asserted-by":"crossref","first-page":"19836","DOI":"10.18632\/oncotarget.24869","article-title":"Molecular imaging with positron emission tomography and computed tomography (PET\/CT) for selecting first-line targeted treatment in metastatic breast cancer: a cost-effectiveness study","volume":"9","author":"Koleva-Kolarova","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.diii.2024.04.004_bib0061","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13550-021-00746-1","article-title":"A preliminary clinical trial to evaluate (64)Cu-NOTA-trastuzumab as a positron emission tomography imaging agent in patients with breast cancer","volume":"11","author":"Lee","year":"2021","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.diii.2024.04.004_bib0062","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2967\/jnumed.117.193888","article-title":"Tumor uptake of (64)Cu-DOTA-trastuzumab in patients with metastatic breast cancer","volume":"59","author":"Mortimer","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0063","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1158\/1078-0432.CCR-22-0094","article-title":"89Zr-panitumumab combined with 18F-FDG PET improves detection and staging of head and neck squamous cell carcinoma","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.diii.2024.04.004_bib0064","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2967\/jnumed.114.144840","article-title":"89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment","volume":"56","author":"Oosting","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0065","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.2967\/jnumed.113.129056","article-title":"Everolimus reduces (89)Zr-bevacizumab tumor uptake in patients with neuroendocrine tumors","volume":"55","author":"van Asselt","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0066","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.2967\/jnumed.112.117218","article-title":"89Zr-bevacizumab PET imaging in primary breast cancer","volume":"54","author":"Gaykema","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0067","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2967\/jnumed.116.180216","article-title":"Molecular drug imaging: (89)Zr-bevacizumab PET in children with diffuse intrinsic pontine glioma","volume":"58","author":"Jansen","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0068","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2967\/jnumed.115.167643","article-title":"89Zr-bevacizumab PET visualizes disease manifestations in patients with von Hippel-Lindau disease","volume":"57","author":"Oosting","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2024.04.004_bib0069","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.3390\/cancers15235639","article-title":"Small antibodies with big applications: nanobody-based cancer diagnostics and therapeutics","volume":"15","author":"Zhang","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.diii.2024.04.004_bib0070","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1007\/s00259-023-06313-1","article-title":"Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga]Ga-nanobody: from bench to bedside","volume":"50","author":"Li","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2024.04.004_bib0071","doi-asserted-by":"crossref","DOI":"10.1177\/1536012117733349","article-title":"First-in-man evaluation of (124)I-PGN650: a PET tracer for detecting phosphatidylserine as a biomarker of the solid tumor microenvironment","volume":"16","author":"Laforest","year":"2017","journal-title":"Mol Imaging"},{"key":"10.1016\/j.diii.2024.04.004_bib0072","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.otohns.2006.07.027","article-title":"Immunoscintigraphy of patients with head and neck carcinomas, with an anti-angiogenetic antibody fragment","volume":"136","author":"Birchler","year":"2007","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.diii.2024.04.004_bib0073","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.3390\/cancers15092620","article-title":"PET\/CT in patients with breast cancer treated with immunotherapy","volume":"15","author":"Vaz","year":"2023","journal-title":"Cancers"}],"container-title":["Diagnostic and Interventional Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211568424001062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211568424001062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T21:03:14Z","timestamp":1759352594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211568424001062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":73,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2211568424001062"],"URL":"https:\/\/doi.org\/10.1016\/j.diii.2024.04.004","relation":{},"ISSN":["2211-5684"],"issn-type":[{"value":"2211-5684","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cutting edge: Promising oncology radiotracers in clinical development","name":"articletitle","label":"Article Title"},{"value":"Diagnostic and Interventional Imaging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diii.2024.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 fran\u00e7aise de radiologie. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}